Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accumulated Expenses (2016 - 2025)

United Therapeutics' Accumulated Expenses history spans 17 years, with the latest figure at $480.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 42.07% year-over-year to $480.9 million; the TTM value through Dec 2025 reached $480.9 million, up 42.07%, while the annual FY2025 figure was $480.9 million, 42.07% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $480.9 million at United Therapeutics, up from $338.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $480.9 million in Q4 2025 and bottomed at $170.8 million in Q4 2021.
  • The 5-year median for Accumulated Expenses is $292.4 million (2023), against an average of $301.7 million.
  • The largest annual shift saw Accumulated Expenses dropped 6.62% in 2021 before it soared 42.07% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $170.8 million in 2021, then surged by 32.2% to $225.8 million in 2022, then rose by 29.5% to $292.4 million in 2023, then grew by 15.77% to $338.5 million in 2024, then skyrocketed by 42.07% to $480.9 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Accumulated Expenses are $480.9 million (Q4 2025), $338.5 million (Q4 2024), and $292.4 million (Q4 2023).